 | Recommended Buy Signal · 3rd Week - May 2007 | |  | Buying SOBM right now is your best chance to
own Microsoft-style profits under $2 per share The SinoBiomed + Bill Gates connection signals epic profits to early SOBM shareholders If you missed out on Microsoft (MSFT), the greatest profit story in stock market history, stop kicking yourself and jump on your next-best opportunity to buy shares of SinoBiomed (SOBM). When Bill Gates initially started Microsoft, he was a college drop-out with no money, yet MSFT went from pennies to command a $300 Billion market cap. You would be a billionaire had you loaded up then – but forget all that ancient history and look closely at what Bill Gates, arguably the world’s richest man is focusing on now: To rid the world of malaria & YOU have the chance get rich in the process. When Bill Gates’ foundation pledged $257.6 million to end the global ravages of malaria, I applauded the humanitarian gesture but also rushed to find the one stock that would increase the most – that’s my job! SinoBiomed (SOBM) has the most profit-potential in Bill Gates’ war-on-malaria I’m the first to tell you about SinoBiomed because I discovered it in the malaria vaccine capital of the world: China. This is the only reason why you can buy SOBM for under $2 a share before this stock skyrockets toward $25. My next report will provide a detailed presentation of SinoBiomed -- I’m giving you the essential info now so you can buy SOBM before Wall Street reacts and drives it 10 times higher. SinoBiomed has already logged tremendous success protecting China against infectious diseases, including malaria and hepatitis. The company has two drugs on the market and 8 more drugs and vaccines awaiting approval or in development – so the “profit-pipeline” is full for early SOBM shareholders. The key point, RIGHT NOW, is that the SinoBiomed story is about the capture the attention of every major Wall Street mutual fund – and what Bill Gates did for Microsoft investors can happen for you as an early SOBM shareholder. SinoBiomed’s new U.S. Patent is your key to
the next 20 Years of Wealth All you need to do is follow this “clear indicator” of tremendous future fortune The headline, “SinoBiomed’s Malaria Vaccine Granted US Patent” was just released from the company’s Shanghai headquarters. When this news floods the American financial news media, you can expect SOBM to more than triple just for starters. The United States Trademark & Patent office has officially granted patent number 7,101,556 B2 for the malaria vaccine (PfCP2.9) that will protect SinoBiomed for 20 years. As an early SOBM shareholder, you own the only company with the rights to make and sell this vaccine throughout the United States for two decades. By that time, you can be retired and excessively wealthy! You have an exclusive advantage if you buy SinoBiomed (SOBM) right now. The company has completed two crucial milestones to garner huge buying attention in the coming weeks: 1. SOBM is the lead stock situation in Bill Gates’ latest humanitarian cause against malaria
2. SOBM has already attained patent-protection in the USA’s behemoth vaccine market Malaria can now be beaten & make SinoBiomed shareholders extremely rich For early shareholders to make huge fortunes, the related company must be the catalyst for significant and economically viable improvement. My priority is to always guide my audience to the next major profit-stock. SinoBiomed is my #1 stock recommendation that can make multi-$millions while also saving millions of lives. Over 2 billion people globally are threatened by malaria, and the annual death toll is over a million. Newer strains of malaria have become drug resistant, and thus mere treatment is no longer an option. Malaria-ridden mosquitoes have even become resistant to insecticides. Only a malaria vaccine – such as the one being developed by SinoBiomed – can save the world and keep an epidemic out of the United States. This moment is your one chance to buy SinoBiomed before it becomes the hottest profit-stock story – DO NOT MISS YOUR CHANCE. SinoBiomed (SOBM) currently trades under $2
-- you should buy immediately 
My full report on SinoBiomed is forthcoming – but do not delay your SOBM stock-purchase. Place your order, then contact SinoBiomed at 1-866-588-0829 or visit the company online at www.SinoBiomed.com to request your shareholder information package. Sincerely on the Contrary, 
Scott S. Fraser
www.NaturalContrarian.com PS – Please review the coupon (below) for the Ultimate Stock-Profit Compass. This investor tool-kit is designed for your independent implementation for years to come. 
IMPORTANT NOTICE AND DISCLAIMER: This stock profile should be viewed as a paid advertisement. In order to enhance public awareness of SinoBiomed and its securities through the distribution of this report, Mass Media Advertising paid the publisher, Nat-Con Publishing, Inc. the sum of $105,000. Nat-Con Publishing applied these funds towards costs associated with creating, printing, and distributing this report and will retain any excess funds as profit. Nat-Con Publishing may receive additional revenue, the amount of which cannot be determined to any degree of certainty, from sales of the Ultimate Stock-Profit Compass in connection with the accompanying offer. No additional sums, however,will be paid by Mass Media Advertising. This publication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. This publication, its publisher, and its editor do not purport to provide a complete analysis of any company’s financial position. The publisher and editor are not, and do not purport to be, registered investment advisors. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. This publication is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the publisher cannot guarantee the accuracy or completeness of the information. This publication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company and/or industry. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company’s products and services, the company’s ability to fund its capital requirements in the near term and long term, pricing pressures, etc. | 
No comments:
Post a Comment